All News

A hospital safety expert says it's now possible to completely eliminate certain adverse events. Pharma can't claim the same yet, but is it time for us to start imagining a time when we can "benchmark perfection"?

Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.

Cordis, the medical-device arm of J&J, took out full-page ads last week to publicize their drug-eluting stents.

Pfizer named first pharmaceutical sponsor of social-networking community custom tailored for physicians and healthcare providers. Sermo CEO Daniel Palestrant explains how the deal will work.

Novartis forced to cut 1,260 jobs due to dwindling pipeline, Zelnorm withdrawal. The company also adds new pharmaceutical division head.

The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end? IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.

In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug.

2008 PharmRep Media Kit

June 2007 Sworn Statement

PharmRep Direct Promo

New search engine gives consumers the ability to manage all their health needs from a central location--and offers pharma the opportunity to reach new patients through targeted search ads

New Web site allows users to create tribute dolls for breast cancer survivors. For every doll made, AZ will donate $1 to charity.

There has been a lot of good news about the Medicare drug benefit in recent weeks. Surveys show a substantial increase in coverage, particularly among low-income seniors. Costs are less than expected; employers continue to offer retiree benefits; major insurers are sticking with the program; and product coverage remains fairly broad. Beneficiaries seem generally satisfied with the program, and the much-feared "doughnut hole" appears less lethal than anticipated (see "A Narrow Gap").

FDA has just premiered a new newsletter on drug safety. There's just one little problem....

Postle fig 6

Postle fig 3

The pace of change

Postle fig 1

Postle fig 5

Search engine giant says industry lags behind on e-marketing

BIO-Europe 2007

Pfizer computers infiltrated by spammers

Two Internet superpowers are invading online consumer-health territory. What does it mean for pharma?

PharmExec November Advertiser Impact Study sellsheet

As expected, must-pass legislation to reauthorize the Prescription Drug User Fee Act (PDUFA IV) has provided a vehicle to renew numerous programs and to establish new policies to ensure the safe use of medications. The measure implements a user-fee agreement issued in January 2007 as well as a similar user-fee plan for medical devices. It also continues incentives for sponsors to study pediatric uses of drugs and devices and gives FDA authority to require postapproval studies. Manufacturers will have to disclose more information about ongoing clinical trials and research results and must revise product labels within a set time frame. There is more funding for FDA oversight of postmarket drug use and for agency information systems. And manufacturers of more risky medications will have to adopt a range of pharmacovigilance activities to ensure appropriate product use.

In this issue, a longtime contributor to this magazine, former FDA official, and generally thoughtful, knowledgeable person concludes his excellent three-part series on drug safety with a look at how risk is communicated to patients and doctors. It's a fine, detailed, subtle piece of work, and I recommend it to you. (See "Failure to Communicate".)

Can BMS make Johnnie and Janie crazy about chemistry?and curing AIDS and cancer?